Published online before print August 11, 2003, doi: 10.1161/01.CIR.0000085163.21752.0A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:939.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events
The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy
From the Sinai Center for Thrombosis Research (V.L.S., A.I.M.), Johns Hopkins University, Baltimore, Md; Columbia University (A.H.G.), New York, NY; Emory University (C.B.N., D.L.M), Atlanta, Ga; Queen’s University (L.T.v.Z.), Kingston, Ontario, Canada; West Virginia University (M.S.F.), Morgantown, WV; Duke Clinical Research Institute (K.R.R.K, R.M.C., C.M.O.), Durham, NC; and Pfizer, Inc (M.G., W.H.), New York, NY.
Reprint requests to Dr Victor L. Serebruany, Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Schapiro Research Bldg–Room 202, Baltimore, MD 21215. E-mail Heartdrug{at}aol.com
Received February 18, 2003; revision received April 24, 2003; accepted April 25, 2003.
Background— Depression after acute coronary syndromes (ACSs) has been identified as an independent risk factor for subsequent cardiac death. Enhanced platelet activation has been hypothesized to represent 1 of the mechanisms underlying this association. Selective serotonin reuptake inhibitors (SSRIs) are known to inhibit platelet activity. Whether treatment of depressed post-ACS patients with SSRIs alters platelet function was not known. Accordingly, we serially assessed the release of established platelet/endothelial biomarkers in patients treated with sertraline vs placebo in the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART).
Methods and Results— Plasma samples (baseline, week 6, and week 16) were collected from patients randomized to sertraline (n=28) or placebo (n=36). Anticoagulants, aspirin, and ADP-receptor inhibitors were permitted in this study. Platelet factor 4, ß-thromboglobulin (ßTG), platelet/endothelial cell adhesion molecule-1, P-selectin, thromboxane B2, 6-ketoprostaglandin F1a, vascular cell adhesion molecule-1, and E-selectin were measured by ELISA. Treatment with sertraline was associated with substantially less release of platelet/endothelial biomarkers than was treatment with placebo. These differences attained statistical significance for ßTG (P=0.03) at weeks 6 and 16 and for P-selectin (P=0.04) at week 16. Repeated-measures ANOVA revealed a significant advantage for sertraline vs placebo for diminishing E-selectin and ßTG concentrations across the entire treatment period.
Conclusions— Treatment with sertraline in depressed post-ACS patients is associated with reductions in platelet/endothelial activation despite coadministration of widespread antiplatelet regimens including aspirin and clopidogrel. The antiplatelet and endothelium-protective properties of SSRIs might represent an attractive additional advantage in patients with depression and comorbid coronary artery and/or cerebrovascular disease.
Key Words: depression • coronary disease • platelets • antidepressants • trials
This article has been cited by other articles:
 |
|
 |
|
  R. K. Riezebos, K.-J. Nauta, A. Honig, F. W. Dekker, and C. E. H. Siegert The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease Nephrol. Dial. Transplant., August 4, 2009; (2009) gfp383v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Seymour and T. B. Benning Depression, cardiac mortality and all-cause mortality Adv. Psychiatr. Treat., March 1, 2009; 15(2): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. POZUELO, G. TESAR, J. ZHANG, M. PENN, K. FRANCO, and W. JIANG Depression and heart disease: What do we know, and where are we headed? Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 59 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liebetrau, B. Steen, and I. Skoog Depression as a Risk Factor for the Incidence of First-Ever Stroke in 85-Year-Olds Stroke, July 1, 2008; 39(7): 1960 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Thomas, D. W. Chapa, E. Friedmann, C. Durden, A. Ross, M. C. Y. Lee, and H.-J. Lee Depression in Patients With Heart Failure: Prevalence, Pathophysiological Mechanisms, and Treatment Crit. Care Nurse, April 1, 2008; 28(2): 40 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Bruce, Y. Guo, K. C. Lawson, A. K. Manatunga, S. F. Auyeung, W. M. McDonald, N. Rushing, A. R. Brown, N. Gilles, M. Emery, et al. Platelet Thromboxane A2 Secretion in Patients With Major Depression Responsive to Electroconvulsive Therapy Psychosom Med, April 1, 2008; 70(3): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Angermann, G. Gelbrich, S. Stork, A. Fallgatter, J. Deckert, H. Faller, G. Ertl, and on behalf of the MOOD-HF Investigators Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF) Eur J Heart Fail, December 1, 2007; 9(12): 1212 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Ziegelstein, K. Parakh, A. Sakhuja, and U. Bhat Depression and Coronary Artery Disease: Is There a Platelet Link? Mayo Clin. Proc., November 1, 2007; 82(11): 1366 - 1368. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Blumenthal, A. Sherwood, S. D. Rogers, M. A. Babyak, P. Murali Doraiswamy, L. Watkins, B. M. Hoffman, C. O'Connell, J. J. Johnson, S. M. Patidar, et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study rationale, design, and methodological issues Clinical Trials, October 1, 2007; 4(5): 548 - 559. [Abstract] [PDF]
|
|
|
|
|
|
F. J. Carod-Artal Are Mood Disorders a Stroke Risk Factor? Stroke, January 1, 2007; 38(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Ziegelstein and S. D. Miller Just a Spoonful of Sugar J. Am. Coll. Cardiol., November 10, 2006; (2006) j.jacc.2006.09.016v1. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weinert and W. Meller Epidemiology of Depression and Antidepressant Therapy After Acute Respiratory Failure Psychosomatics, October 1, 2006; 47(5): 399 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Davidson, D. J. Kupfer, J. T. Bigger, R. M. Califf, R. M. Carney, J. C. Coyne, S. M. Czajkowski, E. Frank, N. Frasure-Smith, K. E. Freedland, et al. Assessment and treatment of depression in patients with cardiovascular disease: national heart, lung, and blood institute working group report. Psychosom Med, September 1, 2006; 68(5): 645 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Whooley Depression and cardiovascular disease: healing the broken-hearted. JAMA, June 28, 2006; 295(24): 2874 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Dolnak Treating Patients for Comorbid Depression, Anxiety Disorders, and Somatic Illnesses J Am Osteopath Assoc, May 1, 2006; 106(5_suppl_2): S1 - S8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kotzailias, T. Andonovski, A. Dukic, V. L. Serebruany, and B. Jilma Antiplatelet Activity During Coadministration of the Selective Serotonin Reuptake Inhibitor Paroxetine and Aspirin in Male Smokers: A Randomized, Placebo-Controlled, Double-blind Trial. J. Clin. Pharmacol., April 1, 2006; 46(4): 468 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. McCaffery, N. Frasure-Smith, M.-P. Dube, P. Theroux, G. A. Rouleau, Q. Duan, and F. Lesperance Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med, March 1, 2006; 68(2): 187 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Serebruany, R. F. Suckow, T. B. Cooper, C. M. O'Connor, A. I. Malinin, K. R. R. Krishnan, L. T. van Zyl, V. Lekht, A. H. Glassman, and Sertraline Antidepressant Heart Attack Randomized Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression Am J Psychiatry, June 1, 2005; 162(6): 1165 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Roose and M. Miyazaki Pharmacologic Treatment of Depression in Patients With Heart Disease Psychosom Med, May 1, 2005; 67(Supplement_1): S54 - S57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Joynt and C. M. O'Connor Lessons From SADHART, ENRICHD, and Other Trials Psychosom Med, May 1, 2005; 67(Supplement_1): S63 - S66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Schulman, P. R. Muskin, and P. A. Shapiro Psychiatry and Cardiovascular Disease Focus, April 1, 2005; 3(2): 208 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L J Tata, J West, C Smith, P Farrington, T Card, L Smeeth, and R Hubbard General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction Heart, April 1, 2005; 91(4): 465 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Rumsfeld and P. M. Ho Depression and Cardiovascular Disease: A Call For Recognition Circulation, January 25, 2005; 111(3): 250 - 253. [Full Text] [PDF]
|
|
|
|
|
|
W. Jiang, M. Kuchibhatla, M. S. Cuffe, E. J. Christopher, J. D. Alexander, G. L. Clary, M. A. Blazing, L. H. Gaulden, R. M. Califf, R. R. Krishnan, et al. Prognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure Circulation, November 30, 2004; 110(22): 3452 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J C Davies, P. R Jackson, J. Potokar, and D. J Nutt Treatment of anxiety and depressive disorders in patients with cardiovascular disease BMJ, April 17, 2004; 328(7445): 939 - 943. [Full Text] [PDF]
|
|
|
|
|
|
B. Ruo and M. Whooley Depression and Health-Related Quality of Life--Reply JAMA, November 12, 2003; 290(18): 2404 - 2404. [Full Text] [PDF]
|
|